Nouscom Announces New Translational Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022
BASEL, Switzerland – 11th April 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced [...]
